Granules India Gets US FDA's Voluntary Action Indicated Classification for Bonthapally, India Unit
MT Newswires Live
Oct 29
Pharmaceutical manufacturing company Granules India (NSE:GRANULES, BOM:532482) received an establishment inspection report (EIR) with an inspection classification of voluntary action indicated (VAI) for its facility at Bonthapally in Hyderabad, India, according to a Wednesday filing to the Indian stock exchanges.
The company had received one observation from the US FDA after the inspection of its active pharmaceutical ingredients (API) facility conducted in June. The company had submitted its response within the stipulated time.
The facility manufactures Paracetamol API. It also has Metformin and Guaifenesin API manufacturing plants in the same facility.
The company's shares were up over 1% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.